Direct oral anticoagulants (DOACs) are increasingly used for anticoagulation, though many physicians remain reluctant to prescribe them due to concerns about bleeding and reversibility.
This review provides practical guidance on the use, laboratory monitoring, and reversal of direct oral anticoagulants to address physician concerns regarding bleeding and reversibility.
Millions of patients in the United States use anticoagulation for a variety of indications, such as the prevention of stroke in those with atrial fibrillation (AF) and the treatment and prevention of venous thrombosis. For over six decades warfarin was the only available oral anticoagulant, but now several DOACs are available and their use has become more prevalent in recent years. In spite of this increased use, many physicians remain reluctant to prescribe DOACs due to concerns about bleeding and reversibility.
Joppa et al. (Sun,) conducted a review in Atrial fibrillation and venous thrombosis. Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated. Direct oral anticoagulants (DOACs) are increasingly used for anticoagulation, though many physicians remain reluctant to prescribe them due to concerns about bleeding and reversibility.